Neurohacker Collective And ChromaDex Partner To Optimize Cellular Health With The Debut Of Qualia NAD+
Portfolio Pulse from Benzinga Newsdesk
Neurohacker Collective has partnered with ChromaDex to launch Qualia NAD+, an NAD+ supplement featuring ChromaDex's patented Niagen ingredient. The product aims to boost NAD+ levels, which are linked to healthy aging and decline with age. A pilot study showed 95% of participants rated Qualia NAD+ as 'excellent' to 'good.' The NAD+ supplementation market is growing, with over half a billion dollars in annual revenue and a projected 13% annual growth rate from 2022 to 2030. Qualia NAD+ includes all three NAD+ precursors and additional ingredients to support NAD+ production. The product is available on neurohacker.com and is expected to expand to additional channels soon.
December 12, 2023 | 3:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ChromaDex's patented Niagen ingredient is featured in Neurohacker Collective's new Qualia NAD+ supplement, which has shown high satisfaction in a pilot study and is positioned to become a leader in the NAD+ supplementation market.
The partnership with Neurohacker Collective and the inclusion of ChromaDex's patented Niagen in the new Qualia NAD+ supplement could positively impact ChromaDex's stock in the short term. The positive results from the pilot study and the growing market for NAD+ supplements suggest a potential increase in demand for Niagen, which could lead to increased revenues for ChromaDex. The company's association with a product that is well-positioned to become a category leader in a growing market segment is likely to be viewed favorably by investors.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80